Neuronal toxicity of efavirenz: A systematic review

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 841-846

  Decloedt, Eric H ^a   Maartens, Gary ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Efavirenz; Neurocognitive impairment; Neurotoxicity

Indexed keywords

8 HYDROXY EFAVIRENZ; ABACAVIR; ABACAVIR PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CANNABINOID; CREATINE KINASE BB; CYTOKINE; DRUG METABOLITE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; NEVIRAPINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CALCIUM HOMEOSTASIS; CEREBROSPINAL FLUID; COGNITION; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MITOCHONDRION; NERVE CELL LESION; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; BENZOXAZINES; BRAIN; CALCIUM; COGNITION DISORDERS; DRUG TOLERANCE; HUMANS; NEURONS; NEUROTOXICITY SYNDROMES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84886636044     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.823396     Document Type: Review

References (57)

1. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011;15(8):1803-18
2. Sustive I(efavirenz) package insert [Internet]. 2012. Available from: Http://packageinserts.bms.com/pi/ pi-sustiva.pdf
3. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. N Engl J Med 1999;341(25):1865-73
4. Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: A review. Int J Neurosci 2010;120(12):739-45
5. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006;29(10):865-74
6. Johnson DH, Gebretsadik T, Shintani A, et al. Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Br J Clin Pharmacol 2013;75(4):997-1006
7. de la Garza CL, Paoletti-Duarte S, Garcia-Martin C, et al. Efavirenz-induced psychosis. AIDS 2001;15(14):1911-12
8. Clifford DB, Evans S, Yang Y, et al. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009;10(6):343-55
9. Manning TG. Efavirenz and psychosis: Is there a link? Aust NZ J Psychiatry 2012;46(7):687-8
10. Zalila H, Elloumi H, Gaha N, et al. Acute psychosis under efavirenz in a HIV patient. Tunis Med 2010;88(2):119-21
11. Salter E, Patel AS. Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B. BMJ Case Rep 2009; Epub ahead of print
12. Poulsen HD, Lublin HK. Efavirenz-induced psychosis leading to involuntary detention. AIDS 2003;17(3):451-3
13. Blanch J, Corbella B, Garcia F, et al. Manic syndrome associated with efavirenz overdose. Clin Infect Dis 2001;33(2):270-1
14. Shah MD, Balderson K. A manic episode associated with efavirenz therapy for HIV infection. AIDS 2003;17(11):1713-14
15. Kenyon C, Mfolozi S, Croxford R, et al. Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia. Br J Clin Pharmacol 2012;74(6):1070-2
16. van Luin M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr 2009;52(2):240-5
17. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15(1):71-5
18. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41(11):1648-53
19. Nunez M, Gonzalez de Requena D, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28(4):399-400
20. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143(10):714-21
21. Siccardi M, Almond L, Schipani A, et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther 2012;92(4):494-502
22. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS clinical trials group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012;22(12):858-67
23. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009;19(4):300-9
24. Belanger AS, Caron P, Harvey M, et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009;37(9):1793-6
25. Minuesa G, Huber-Ruano I, Pastor-Anglada M, et al. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther 2011;132(3):268-79
26. Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol Ther 2009;123(1):80-104
27. Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood ;233(9):1149-60
28. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: Summary of current knowledge and recommendations for further research. Antiviral Res 2009;82(2):A99-109
29. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: An adult aids clinical trials group study. J Infect Dis 2005;192(11):1931-42
30. Elens L, Vandercam B, Yombi JC, et al. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010;11(9):1223-34
31. Swart M, Ren Y, Smith P, et al. ABCB1 >G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front Genet 2012;3:236
32. Avery LB, Sacktor N, McArthur JC, et al. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: Applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Chemother 2013;57(3):1409-14
33. Winston A, Puls R, Kerr SJ, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: A randomized, controlled study. HIV Med 2012;13(4):245-51
34. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011;76(16):1403-9
35. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol 2011;17(1):3-16
36. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010;75(23):2087-96
37. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010;74(16):1260-6
38. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012;18(5):388-99
39. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 2012;343(3):696-703
40. Streck EL, Scaini G, Rezin GT, et al. Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 2008;23(4):485-92
41. Zhang SF, Hennessey T, Yang L, et al. Impaired brain creatine kinase activity in huntington's disease. Neurodegener Dis 2011;8(4):194-201
42. Blas-Garcia A, Apostolova N, Ballesteros D, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010;52(1):115-25
43. Swerdlow RH. Brain aging, alzheimer's disease, and mitochondria. Biochim Biophys Acta 2011;1812(12):1630-9
44. Streck EL, Ferreira GK, Scaini G, et al. Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions. Neurochem Res 2011;36(6):962-6
45. O'Mahony SM, Myint AM, Steinbusch H, et al. Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. Neuroimmunomodulation 2005;12(5):293-8
46. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits. Depress Anxiety 2013;30(4):297-306
47. Hecht M, Harrer T, Buttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS 2013. [Epub ahead of print]
48. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel. JAMA 2012;308(4):387-402
49. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010. Available from: Http://www.who.int/hiv/pub/arv/ adult2010/en/index.html
50. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: Crucial issues for high-burden countries. Antivir Ther 2009;14(8):1039-43
51. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An adult AIDS clinical trials group study. AIDS 2004;18(18):2391-400
52. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011;19(4):137-42
53. Enting RH, Hoetelmans RM, Lange JM, et al. Antiretroviral drugs and the central nervous system. AIDS 1998;12(15):1941-55
54. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002;16(9):595-609
55. Letendre SL, Capparelli EV, Ellis RJ, et al. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. the HIV neurobehavioral research center group. Antimicrob Agents Chemother 2000;44(8):2173-5
56. Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005;49(6):2504-6
57. Zhou XJ, Havlir DV, Richman DD, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14(18):2869-76